I-Mab (天境生物) IPO - Everest deal a valuation booster

I-Mab launched the book building to raise up to USD 111 million via a listing on NASDAQ. In our previous notes, we covered the company’s key pipeline products, including TJ202 (CD38 antibody), TJ101 (long-acting growth hormone), enoblituzumab (B7-H3 antibody) and TJ107 (long-acting IL07). We discussed clinical trial results, licensing agreement and timelines of these four products. On its core product, TJ202, we were of the view that its efficacy appears to be inferior to the benchmark pro...